Almirall
Almirall SA is a Spanish biopharmaceutical company specializing in medical dermatology and skin health therapeutics. The company researches, manufactures, and commercializes prescription therapies for psoriasis, actinic keratosis, atopic dermatitis, and acne, highlighted by Ilumetri (tildrakizumab), Klisyri, and Wynzora. Main revenue drivers comprise global commercial sales of prescription dermatological pharmaceuticals alongside licensing milestone receipts and active pharmaceutical ingredient sales. Almirall serves dermatologists, hospital networks, prescription pharmacies, and skin disease patients across Europe, North America, and Asia. The company holds a market-leading European position in prescription medical dermatology and inflammatory skin disease treatments. Headquartered in Barcelona, Spain, Almirall SA is listed on the Bolsa de Madrid.
4 of the funds FundTelligence covers report a position in Almirall.
- Legal name
- Almirall SA
- Sector
- Health Care
- Country
- Spain
- Funds holding it
- 4
Funds holding Almirall
- HealthInvest Small & Mid Cap Healthcare — HealthInvest · 3.0 % (partially disclosed portfolio, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.01 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.01 % (partially disclosed portfolio, June 2026)